JP2023530969A - γ-グロビン遺伝子発現を活性化する方法、および組成物 - Google Patents
γ-グロビン遺伝子発現を活性化する方法、および組成物 Download PDFInfo
- Publication number
- JP2023530969A JP2023530969A JP2022577265A JP2022577265A JP2023530969A JP 2023530969 A JP2023530969 A JP 2023530969A JP 2022577265 A JP2022577265 A JP 2022577265A JP 2022577265 A JP2022577265 A JP 2022577265A JP 2023530969 A JP2023530969 A JP 2023530969A
- Authority
- JP
- Japan
- Prior art keywords
- ssodn
- sequence
- gene
- seq
- sgrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 title claims abstract description 83
- 230000014509 gene expression Effects 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 51
- 230000003213 activating effect Effects 0.000 title claims abstract description 14
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 title claims description 73
- 239000000203 mixture Substances 0.000 title claims description 24
- 238000010362 genome editing Methods 0.000 claims abstract description 159
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 28
- 230000000295 complement effect Effects 0.000 claims abstract description 24
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 24
- 101150075675 tatC gene Proteins 0.000 claims abstract description 18
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims abstract description 10
- 208000007056 sickle cell anemia Diseases 0.000 claims abstract description 10
- 230000001105 regulatory effect Effects 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 113
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 62
- 101001031961 Homo sapiens Hemoglobin subunit gamma-2 Proteins 0.000 claims description 54
- 108020004414 DNA Proteins 0.000 claims description 50
- 230000035772 mutation Effects 0.000 claims description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 102100038614 Hemoglobin subunit gamma-1 Human genes 0.000 claims description 34
- 238000012217 deletion Methods 0.000 claims description 31
- 230000037430 deletion Effects 0.000 claims description 31
- 101001031977 Homo sapiens Hemoglobin subunit gamma-1 Proteins 0.000 claims description 30
- 239000013612 plasmid Substances 0.000 claims description 25
- 108020005004 Guide RNA Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 238000003780 insertion Methods 0.000 claims description 19
- 230000037431 insertion Effects 0.000 claims description 19
- 108020004999 messenger RNA Proteins 0.000 claims description 18
- 101150083167 HBG1 gene Proteins 0.000 claims description 14
- 101150034267 HBG2 gene Proteins 0.000 claims description 14
- 238000010459 TALEN Methods 0.000 claims description 13
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 13
- 108091033409 CRISPR Proteins 0.000 claims description 11
- 108091081021 Sense strand Proteins 0.000 claims description 11
- 238000011144 upstream manufacturing Methods 0.000 claims description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 claims description 7
- 208000005980 beta thalassemia Diseases 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 102000004389 Ribonucleoproteins Human genes 0.000 claims 1
- 108010081734 Ribonucleoproteins Proteins 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 abstract description 51
- 238000005516 engineering process Methods 0.000 abstract description 15
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 14
- 230000035897 transcription Effects 0.000 abstract description 13
- 238000013518 transcription Methods 0.000 abstract description 13
- 108010044495 Fetal Hemoglobin Proteins 0.000 abstract description 7
- 102100036646 Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial Human genes 0.000 description 43
- 101001072655 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial Proteins 0.000 description 43
- 108010054147 Hemoglobins Proteins 0.000 description 35
- 102000001554 Hemoglobins Human genes 0.000 description 35
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 27
- 238000001890 transfection Methods 0.000 description 26
- 102100031690 Erythroid transcription factor Human genes 0.000 description 24
- 238000004520 electroporation Methods 0.000 description 22
- 230000000925 erythroid effect Effects 0.000 description 22
- 101710100588 Erythroid transcription factor Proteins 0.000 description 20
- 230000000875 corresponding effect Effects 0.000 description 19
- 230000004069 differentiation Effects 0.000 description 19
- 230000001976 improved effect Effects 0.000 description 17
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 16
- 238000001514 detection method Methods 0.000 description 16
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 14
- 208000034737 hemoglobinopathy Diseases 0.000 description 14
- 101710163270 Nuclease Proteins 0.000 description 13
- 101000891113 Homo sapiens T-cell acute lymphocytic leukemia protein 1 Proteins 0.000 description 12
- 239000000969 carrier Substances 0.000 description 12
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000008439 repair process Effects 0.000 description 12
- 239000003623 enhancer Substances 0.000 description 11
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 10
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 10
- 239000012097 Lipofectamine 2000 Substances 0.000 description 10
- 101000702553 Schistosoma mansoni Antigen Sm21.7 Proteins 0.000 description 10
- 101000714192 Schistosoma mansoni Tegument antigen Proteins 0.000 description 10
- 102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 102100022976 B-cell lymphoma/leukemia 11A Human genes 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 8
- 101150086355 HBG gene Proteins 0.000 description 8
- 101000903703 Homo sapiens B-cell lymphoma/leukemia 11A Proteins 0.000 description 8
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 8
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 6
- 108700011215 E-Box Elements Proteins 0.000 description 6
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 6
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 101100290388 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rnp-2 gene Proteins 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 108091028113 Trans-activating crRNA Proteins 0.000 description 6
- 108700009124 Transcription Initiation Site Proteins 0.000 description 6
- 102000004338 Transferrin Human genes 0.000 description 6
- 108090000901 Transferrin Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 230000005782 double-strand break Effects 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 210000003917 human chromosome Anatomy 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108091006106 transcriptional activators Proteins 0.000 description 6
- 239000012581 transferrin Substances 0.000 description 6
- -1 "CRISPR-Cas" Proteins 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 108010044267 Abnormal Hemoglobins Proteins 0.000 description 4
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 4
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 4
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 4
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 description 4
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 108091028664 Ribonucleotide Proteins 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- 208000002903 Thalassemia Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 102000018146 globin Human genes 0.000 description 4
- 108060003196 globin Proteins 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 150000003278 haem Chemical class 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000006780 non-homologous end joining Effects 0.000 description 4
- 239000002336 ribonucleotide Substances 0.000 description 4
- 125000002652 ribonucleotide group Chemical group 0.000 description 4
- 238000007480 sanger sequencing Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 101100252357 Caenorhabditis elegans rnp-1 gene Proteins 0.000 description 2
- 238000001353 Chip-sequencing Methods 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 101100493741 Homo sapiens BCL11A gene Proteins 0.000 description 2
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100025169 Max-binding protein MNT Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 108010053584 alpha-Globins Proteins 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037429 base substitution Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000009547 development abnormality Effects 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 108010089558 erythroid Kruppel-like factor Proteins 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 208000020451 hereditary persistence of fetal hemoglobin Diseases 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001718 repressive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 108091006107 transcriptional repressors Proteins 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (29)
- γ-グロビン遺伝子発現を活性化する方法であって、
遺伝子編集技術によってγ-グロビン遺伝子調節領域におけるセンス鎖またはアンチセンス鎖に、GATAまたはTATC配列を人為的に導入して、γ-グロビン遺伝子の調節領域においてGATAモチーフを含むエンハンサー要素を形成することを含む、方法。 - GATAまたはTATC配列の導入は、配列の削除、配列の挿入、配列の変異、またはそれらの組合せにより実現される、
請求項1に記載の方法。 - GATAモチーフは、WGATAR配列、または対応するアンチセンス相補配列YTATCWであり、ただし、Wは、TまたはAであり、Rは、AまたはGであり、Yは、TまたはCである、
請求項1に記載の方法。 - 前記エンハンサー要素には、NTGモチーフまたはNAGモチーフ、または対応するアンチセンス相補配列がさらに含まれ、
ただし、Nは、A、G、CまたはTである、
請求項1に記載の方法。 - 前記GATAモチーフとNTGモチーフまたはNAGモチーフとの距離が7~8塩基であり、且つ前記NTGモチーフまたはNAGモチーフが前記GATAモチーフの上流に位置する、
請求項4に記載の方法。 - GATAまたはTATC配列が含まれる、遺伝子編集用ssODN。
- 前記ssODNには、5′相同アーム、置換配列、3′相同アームが含まれる、
請求項6に記載のssODN。 - 前記ssODNにおける5′相同アームと3′相同アームとが対称的または非対称的であり、5′相同アームと3′相同アームの長さが20~300ntである、
請求項7に記載のssODN。 - 前記ssODNにおける5′相同アームまたは3′相同アームは、擬似編集領域DNAのセンス鎖またはアンチセンス鎖から選ばれる、
請求項7に記載のssODN。 - 前記ssODNにおける置換配列の塩基の数が0~6である、
請求項7に記載のssODN。 - 前記ssODNにおける5′相同アームの3′末端と3′相同アームの5′末端との距離が0~20塩基である、
請求項7に記載のssODN。 - 前記ssODNには、SEQ ID NO:4~SEQ ID NO:7、SEQ ID NO:9~SEQ ID NO:22、SEQ ID NO:24、SEQ ID NO:26、SEQ ID NO:28~SEQ ID NO:31で表される配列、またはそのアンチセンス相補配列から選ばれるものが含まれる、
請求項6に記載のssODN。 - 前記ssODNには、SEQ ID NO:40~SEQ ID NO:65で表される配列、またはそのアンチセンス相補配列から選ばれるものが含まれる、
請求項6に記載のssODN。 - 前記ssODNが化学修飾されたものであり、その5′および3′端がホスホロチオエートで修飾されたヌクレオチドである、
請求項6に記載のssODN。 - HBG1またはHBG2調節領域におけるDNAセンス鎖またはアンチセンス鎖と一部または全部相補するガイド配列が含まれる、
sgRNA。 - 前記HBG1調節領域における配列は、SEQ ID NO:1で表される、
請求項15に記載のsgRNA。 - 前記HBG2調節領域における配列は、SEQ ID NO:2で表される、
請求項15に記載のsgRNA。 - 前記sgRNA分子のガイドRNA配列の対応するDNA配列は、SEQ ID NO:32~SEQ ID NO:39で表される配列から選ばれるものと一部または全部同様である、請求項15に記載のsgRNA。
- 前記sgRNAは、SEQ ID NO:69~SEQ ID NO:76で表される配列から選ばれるいずれか1種または複数種である、
請求項15に記載のsgRNA。 - 請求項6~14のいずれか一項に記載のssODN、および標的HBG1またはHBG2遺伝子調節領域における遺伝子編集システムが含まれる、
遺伝子編集用組成物。 - 前記遺伝子編集システムは、CRISPR-Cas編集システム、TALEN編集システム、ZFN編集システムである、
請求項20に記載の組成物。 - 前記CRISPR-Cas編集システムは、CRISPR-Cas9、CRISPR-Cas12システムである、
請求項21に記載の組成物。 - 前記組成物のうち、CRISPR-Cas編集システムは、ガイドRNAおよびCasタンパク質からなるリボ核タンパク質複合体である、
請求項21に記載の組成物。 - 前記組成物のうち、CRISPR-Cas編集システムは、Casタンパク質をコードするmRNAおよびgRNAからなるRNA複合体である、
請求項21に記載の組成物。 - 前記組成物のうち、CRISPR-Cas編集システムは、Casタンパク質およびgRNAを発現するプラスミドである、
請求項21に記載の組成物。 - 前記組成物には、請求項15~19のいずれか一項に記載のsgRNAが含まれ、
前記sgRNAは、化学合成されたもの、またはインビトロ転写されたものである、
請求項20に記載の組成物。 - γ-グロビン遺伝子を活性化するキットであって、
(1)請求項6~14のいずれか一項に記載のssODNと、
(2)請求項15~19のいずれか一項に記載のsgRNAと、
(3)Cas9またはCas12タンパク質を発現する担体、Cas9またはCas12タンパク質、Cas9またはCas12タンパク質に対応するmRNAのうちの少なくとも1種と、を含む、
ことを特徴とするキット。 - 電気的転写方法により請求項20~26のいずれか一項に記載の組成物を造血幹細胞に導入して得られる、ことを特徴とする造血幹細胞。
- 請求項6~14のいずれか一項に記載のssODN、請求項15~19のいずれか一項に記載のsgRNA、請求項20~26のいずれか一項に記載の組成物、請求項27に記載のキット、請求項28に記載の造血幹細胞の、β-地中海貧血症または鎌型赤血球貧血症を治療するための細胞または薬物の調製における使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010616648.7 | 2020-07-01 | ||
CN202010616648.7A CN111876416B (zh) | 2020-07-01 | 2020-07-01 | 激活γ-珠蛋白基因表达的方法和组合物 |
PCT/CN2020/101936 WO2022000572A1 (zh) | 2020-07-01 | 2020-07-14 | 激活γ-珠蛋白基因表达的方法和组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023530969A true JP2023530969A (ja) | 2023-07-20 |
Family
ID=73157578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022577265A Pending JP2023530969A (ja) | 2020-07-01 | 2020-07-14 | γ-グロビン遺伝子発現を活性化する方法、および組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230310506A1 (ja) |
EP (1) | EP4177343A1 (ja) |
JP (1) | JP2023530969A (ja) |
CN (2) | CN111876416B (ja) |
AU (1) | AU2020455671A1 (ja) |
WO (1) | WO2022000572A1 (ja) |
ZA (1) | ZA202213480B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022272042A2 (en) * | 2021-06-25 | 2022-12-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Primordial germ cells |
CN115851706A (zh) * | 2021-09-24 | 2023-03-28 | 华东师范大学 | 一种碱基编辑系统及其应用 |
CN114848851A (zh) * | 2022-04-29 | 2022-08-05 | 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) | 治疗β-地中海贫血的药物 |
CN116790593B (zh) * | 2023-06-28 | 2024-05-10 | 贵州医科大学 | 一种激活γ珠蛋白表达的sgRNA及其CRISPR/Cas9复合体与应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018011114A (es) * | 2016-03-14 | 2019-02-20 | Editas Medicine Inc | Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías. |
WO2017191503A1 (en) * | 2016-05-05 | 2017-11-09 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
AU2018352592A1 (en) * | 2017-10-16 | 2020-06-04 | Beam Therapeutics, Inc. | Uses of adenosine base editors |
CN109722414A (zh) * | 2017-10-27 | 2019-05-07 | 博雅辑因(北京)生物科技有限公司 | 一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基 |
CN110106203B (zh) * | 2019-05-24 | 2023-08-11 | 中国医学科学院血液病医院(血液学研究所) | 一种新型hbb过表达载体及其设计方法和应用 |
-
2020
- 2020-07-01 CN CN202010616648.7A patent/CN111876416B/zh active Active
- 2020-07-14 WO PCT/CN2020/101936 patent/WO2022000572A1/zh unknown
- 2020-07-14 EP EP20942540.4A patent/EP4177343A1/en active Pending
- 2020-07-14 AU AU2020455671A patent/AU2020455671A1/en active Pending
- 2020-07-14 US US18/010,448 patent/US20230310506A1/en active Pending
- 2020-07-14 JP JP2022577265A patent/JP2023530969A/ja active Pending
- 2020-07-14 CN CN202080032995.3A patent/CN115943209A/zh active Pending
-
2022
- 2022-12-13 ZA ZA2022/13480A patent/ZA202213480B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA202213480B (en) | 2023-09-27 |
WO2022000572A1 (zh) | 2022-01-06 |
US20230310506A1 (en) | 2023-10-05 |
AU2020455671A1 (en) | 2023-02-02 |
EP4177343A1 (en) | 2023-05-10 |
CN111876416B (zh) | 2021-09-03 |
CN111876416A (zh) | 2020-11-03 |
CN115943209A (zh) | 2023-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240002843A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
KR102532663B1 (ko) | 베타 이상헤모글로빈증의 치료를 위한 crispr/cas-관련 방법 및 조성물 | |
AU2016225179B2 (en) | Materials and methods for treatment of hemoglobinopathies | |
JP2023530969A (ja) | γ-グロビン遺伝子発現を活性化する方法、および組成物 | |
Antoniou et al. | Base and prime editing technologies for blood disorders | |
WO2017191503A1 (en) | Materials and methods for treatment of hemoglobinopathies | |
US20210180091A1 (en) | Materials and methods for treatment of hemoglobinopathies | |
US20210130817A1 (en) | Gene Editing System and Gene Editing Method | |
US20220259578A1 (en) | Materials and methods for treatment of hemoglobinopathies | |
Antoniou et al. | Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression | |
CN112391410B (zh) | 一种sgRNA及其在修复内含子异常剪接中的应用 | |
Suwito et al. | A Review of CRISPR Cas9 for SCA: Treatment Strategies and Could Target β-globin Gene and BCL11A Gene using CRISPR Cas9 Prevent the Patient from Sickle Cell Anemia? | |
EP4373846A1 (en) | A method for in vivo gene therapy to cure scd without myeloablative toxicity | |
Suwito et al. | Choirotussanijjah. A Review of CRISPR Cas9 for SCA: Treatment Strategies and Could Target β-globin Gene and BCL11A Gene using CRISPR Cas9 Prevent the Patient from Sickle Cell Anemia? Open Access Maced J Med Sci. 2023 Feb 03; 11 (F): 95-106 | |
CN117940566A (zh) | 用于治疗血红蛋白病的系统和方法 | |
CN115873850A (zh) | 腺嘌呤碱基编辑系统及其应用 | |
CN118127006A (zh) | 用于治疗β-血红蛋白病的CRISPR/CAS相关方法和组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221214 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240305 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240523 |